Advances in the treatment of testicular cancer

Germ cell tumors (GCT) are relatively uncommon, accounting for only 1% of male malignancies in the United States. It has become an important oncological disease for several reasons. It is the most common malignancy in young men 15-35 years old. GCTs are among a unique numbers of neoplasms where bioc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehrlich, Yaron, Margel, David, Lubin, Marc Alan, Baniel, Jack
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708227/
https://www.ncbi.nlm.nih.gov/pubmed/26816836
http://dx.doi.org/10.3978/j.issn.2223-4683.2015.06.02
_version_ 1782409425208737792
author Ehrlich, Yaron
Margel, David
Lubin, Marc Alan
Baniel, Jack
author_facet Ehrlich, Yaron
Margel, David
Lubin, Marc Alan
Baniel, Jack
author_sort Ehrlich, Yaron
collection PubMed
description Germ cell tumors (GCT) are relatively uncommon, accounting for only 1% of male malignancies in the United States. It has become an important oncological disease for several reasons. It is the most common malignancy in young men 15-35 years old. GCTs are among a unique numbers of neoplasms where biochemical markers play a critical role. Finally, it is a model of curable cancer. In this review we discuss cancer epidemiology, genetics, and therapeutic principles. Recent advances in the management of stage I GCT and controversies in the management of post chemotherapy residual mass are presented.
format Online
Article
Text
id pubmed-4708227
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-47082272016-01-26 Advances in the treatment of testicular cancer Ehrlich, Yaron Margel, David Lubin, Marc Alan Baniel, Jack Transl Androl Urol Review Article Germ cell tumors (GCT) are relatively uncommon, accounting for only 1% of male malignancies in the United States. It has become an important oncological disease for several reasons. It is the most common malignancy in young men 15-35 years old. GCTs are among a unique numbers of neoplasms where biochemical markers play a critical role. Finally, it is a model of curable cancer. In this review we discuss cancer epidemiology, genetics, and therapeutic principles. Recent advances in the management of stage I GCT and controversies in the management of post chemotherapy residual mass are presented. AME Publishing Company 2015-06 /pmc/articles/PMC4708227/ /pubmed/26816836 http://dx.doi.org/10.3978/j.issn.2223-4683.2015.06.02 Text en 2015 Translational Andrology and Urology. All rights reserved.
spellingShingle Review Article
Ehrlich, Yaron
Margel, David
Lubin, Marc Alan
Baniel, Jack
Advances in the treatment of testicular cancer
title Advances in the treatment of testicular cancer
title_full Advances in the treatment of testicular cancer
title_fullStr Advances in the treatment of testicular cancer
title_full_unstemmed Advances in the treatment of testicular cancer
title_short Advances in the treatment of testicular cancer
title_sort advances in the treatment of testicular cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708227/
https://www.ncbi.nlm.nih.gov/pubmed/26816836
http://dx.doi.org/10.3978/j.issn.2223-4683.2015.06.02
work_keys_str_mv AT ehrlichyaron advancesinthetreatmentoftesticularcancer
AT margeldavid advancesinthetreatmentoftesticularcancer
AT lubinmarcalan advancesinthetreatmentoftesticularcancer
AT banieljack advancesinthetreatmentoftesticularcancer

Ejemplares similares